2005
DOI: 10.1378/chest.128.5.3585
|View full text |Cite
|
Sign up to set email alerts
|

The Physical and Biological Doses of Methacholine Are Different for Mefar MB3 and Jaeger APS Sidestream Nebulizers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
16
0

Year Published

2006
2006
2017
2017

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 11 publications
(17 citation statements)
references
References 15 publications
1
16
0
Order By: Relevance
“…The procedure was adapted from the European Community Respiratory Health protocol. As previously described elsewhere [23], the number of false positives at a cumulative dose of 1.2 mg was high. Therefore, a cumulative dose of 0.6 mg was chosen as a cut-off value for the analyses.…”
Section: Study Design and Data Collectionsupporting
confidence: 57%
See 1 more Smart Citation
“…The procedure was adapted from the European Community Respiratory Health protocol. As previously described elsewhere [23], the number of false positives at a cumulative dose of 1.2 mg was high. Therefore, a cumulative dose of 0.6 mg was chosen as a cut-off value for the analyses.…”
Section: Study Design and Data Collectionsupporting
confidence: 57%
“…The strengths of the present study were: 1) a good response to the questionnaire part of the study among a large populationbased sample of rural subjects; 2) the use of validated questionnaire instruments [23]; and 3) objective measurements of sensitisation, lung function and BHR in approximately half of the population. To reduce selection bias, subjects were a priori randomly divided in two groups.…”
Section: Discussionmentioning
confidence: 99%
“…The MB3 nebulisers were shown by Praml [20] to have a particle size 5.4 μm mass median aerodynamic diameter (MMAD). Whereas Ryan [21] demonstrated 70% of particle size was of <5 μm MMAD for the Devilbiss 646 nebuliser.…”
Section: Discussionmentioning
confidence: 99%
“…Bronchial hyperresponsiveness (BHR) was tested using APS nebulizers (Viasys Health Care) according to the adapted ECRHS protocol for a stepwise methacholine challenge [29,30]. The ISAAC Phase Two protocol was not suitable for the SOLAR II age group.…”
Section: Methodsmentioning
confidence: 99%